ArticleExperimental hematology & oncology2018
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.
Article in Experimental hematology & oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience.Cancer immunology, immunotherapy : CII · 2022Trial
- Trial
- Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial.Frontiers in immunology · 2019Trial
- WT1 gene: a potential therapeutic target for multiple cancer treatment strategies.Clinical and experimental medicine · 2025Review
- Review
- Advances in vaccine development for cancer prevention and treatment in Lynch Syndrome.Molecular aspects of medicine · 2023Review
- ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas' disease.NPJ vaccines · 2023Article
- Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial.Cancer immunology, immunotherapy : CII · 2022Article
- A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies.Scientific reports · 2021Article
- Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.Journal for immunotherapy of cancer · 2021Article
- Functional Recognition by CD8+ T Cells of Epitopes with Amino Acid Variations Outside Known MHC Anchor or T Cell Receptor Recognition Residues.International journal of molecular sciences · 2020Article
- Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival.Bone marrow transplantation · 2020Article
- Molecular update on biology of Wilms Tumor 1 gene and its applications in acute myeloid leukemia.American journal of blood research · 2020Review
- Identification ofBiomarker research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe optimal strategy for vaccination to induce CD8
methodsA pilot randomized study in HLA-A02
resultsAll patients finished the induction phase without any major toxicity except mild transient local injection reaction. One patient on the Montanide arm developed aseptic ulceration at two vaccine sites which healed without antibiotics. Three of 4 patients on the Montanide arm had a decreased expression of WT1 after WT1 vaccination, and two of them demonstrated generation of WT1-specific cytotoxic CD8
conclusionsWT1 peptide vaccine with Montanide as an adjuvant induces detectable WT1-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.